Table 3.
Correlation of HAVCR2 expression with clinicopathological features in PCa patients.
| Clinical features | TMA | TCGA | ||||||
|---|---|---|---|---|---|---|---|---|
| Case | Low, n (%) | High, n (%) | P | Case | Low, n (%) | High, n (%) | P | |
| Tissue | ||||||||
| Cancer | 70 | 6 (8.57) | 64 (91.43) | 0.260 | 427 | 213 (49.88) | 214 (50.12) | – |
| Non-cancer | 10 | 2 (20.00) | 8 (80.00) | – | 0 | – | – | – |
| Age (years) | ||||||||
| ≤60 | 14 | 2 (14.29) | 12 (85.71) | 0.556 | 190 | 107 (56.32) | 83 (43.68) | 0.017 * |
| >60 | 66 | 6 (9.09) | 60 (90.91) | – | 237 | 106 (44.73) | 131 (55.27) | – |
| Gleason score | ||||||||
| ≤8 | 46 | 3 (6.52) | 43 (93.48) | 0.396 | 300 | 172 (57.33) | 128 (42.67) | <0.001 *** |
| >8 | 24 | 3 (12.50) | 21 (87.50) | – | 127 | 41 (32.28) | 86 (67.72) | – |
| Serum PSA levels (ng/ml) | ||||||||
| ≤2 | – | – | – | – | 378 | 194 (51.32) | 184 (48.68) | 0.010 ** |
| >2 | – | – | – | – | 35 | 10 (28.57) | 25 (71.43) | – |
| Pathological grade | ||||||||
| pT1-pT2 | 4 | 0 (0.00) | 4 (100.00) | 0.525 | – | – | – | – |
| pT3 | 65 | 6 (9.23) | 59 (90.77) | – | – | – | – | – |
| Tumor stage | ||||||||
| T1 | 0 | – | – | - | 153 | 88 (57.52) | 61 (42.48) | 0.053 |
| T2 | 42 | 4 (9.52) | 38 (90.48) | 0.787 | 155 | 74 (47.74) | 80 (52.26) | – |
| T3 | 14 | 1 (7.14) | 13 (92.86) | – | 48 | 22 (45.83) | 32 (54.17) | – |
| T4 | 0 | – | – | – | 1 | 0 (0.00) | 1 (100.00) | – |
| Lymph nodemetastasis | ||||||||
| N0 | 56 | 5 (8.93) | 51 (91.07) | – | 303 | 154 (50.83) | 149 (49.17) | 0.002 ** |
| N1 | 0 | – | – | – | 69 | 21 (30.43) | 48 (69.57) | – |
| Distant metastasis | ||||||||
| M0 | 56 | 5 (8.93) | 51 (91.07) | – | 401 | 199 (49.63) | 202 (50.37) | 0.574 |
| M1 | 0 | – | – | – | 3 | 1 (33.33) | 2 (66.67) | – |
＊means the difference is significant at the 0.05 level ,** means the difference is significant at the 0.01 level, *** means the difference is significant at the 0.01 level.